Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

35.37USD
17 Nov 2017
Change (% chg)

$-0.19 (-0.53%)
Prev Close
$35.56
Open
$35.33
Day's High
$35.49
Day's Low
$35.17
Volume
5,980,857
Avg. Vol
4,855,759
52-wk High
$36.78
52-wk Low
$30.51

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $214,682.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.55

Financials

  Industry Sector
P/E (TTM): -- 31.19 16.41
EPS (TTM): -- -- --
ROI: -- 14.93 10.66
ROE: -- 16.20 14.26

FDA expands approval for Pfizer cancer drug Sutent

The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney.

17 Nov 2017

U.S. FDA expands approval for Pfizer cancer drug Sutent

Nov 16 The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney.

17 Nov 2017

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

LONDON Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service.

16 Nov 2017

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

LONDON, Nov 16 Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service.

16 Nov 2017

UPDATE 1-Pfizer creates chief operating officer role for Bourla

NEW YORK, Nov 13 Drugmaker Pfizer Inc has promoted Albert Bourla to the newly created post of chief operating officer, freeing up Chief Executive Officer Ian Read to focus more on long-term strategy and engaging with government and industry leaders.

13 Nov 2017

BRIEF-Pfizer names Albert Bourla chief operating officer

* Pfizer - ‍albert Bourla has been group president of co's innovative health business since beginning of 2016​

13 Nov 2017

Pfizer exits China joint venture for generic drugs

Nov 10 Pfizer Inc said on Friday it has sold its 49 percent stake to exit a joint venture it had set up with China's Zhejiang Hisun Pharmaceuticals in 2012 to develop and market generic drugs.

11 Nov 2017

UPDATE 1-Merck KGaA tones down outlook but consumer health shines

* Sales, profit to hit lower end of target ranges on strong eur

09 Nov 2017

Novartis takes fight to Pfizer's Ibrance with new Kisqali data

ZURICH New data from Novartis's breast cancer drug Kisqali underscored its effectiveness in pre-menopausal women, the Swiss drugmaker said, amid efforts to muscle in on turf dominated by rival Pfizer's Ibrance.

08 Nov 2017

UPDATE 1-Novartis takes fight to Pfizer's Ibrance with new Kisqali data

* Class of CDK4/6 cancer drugs getting crowded (Adds details, company and analyst comment)

08 Nov 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $138.00 -0.87
Novartis AG (NOVN.S) CHF83.30 +0.90
Merck & Co., Inc. (MRK.N) $55.20 +0.03
Roche Holding Ltd. (ROG.S) CHF230.10 +1.10
Roche Holding Ltd. (RO.S) CHF233.30 +1.30
Abbott Laboratories (ABT.N) $55.56 +0.02
Bayer AG (BAYGn.DE) €107.55 -0.35
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €75.43 -0.54
AstraZeneca plc (AZN.L) 4,975.00 --

Earnings vs. Estimates